Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia
ADELAIDE, AUS, Jul 09, 2021 - (ACN Newswire) - The largest Australian full-service CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client Tetherex Pharmaceuticals on first patient dosing for its Phase 1 vaccine clinical trial.
Tetherex Pharmaceuticals, Inc. is a privately held, clinical stage biopharmaceutical company focused on development of selectin inhibitor therapeutics for the treatment of a broad range of inflammatory diseases and single-cycle adenovirus vaccines for multiple infectious diseases and cancer indications.
Avance Clinical Chief Scientific Officer Dr Gabriel Kremmidiotis said:
"The exciting aspect of the Tetherex product is the potential to vaccinate using a nasal spray. Administering the vaccine via the same route that the virus uses to get into our bodies, may result in more effective protection compared to the first generation Covid-19 vaccine products currently being administered as injectables. Commencement of dosing with the Tetherex Covid-19 vaccine product constitutes a major achievement for the Avance Clinical team who played a key role in supporting Tetherex in gaining regulatory approval to conduct the First-in-Human trial with their exciting vaccine candidate."
According to Tetherex Pharmaceutical's announcement:
Tetherex Pharmaceuticals has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform. The platform will be used to target multiple infectious diseases, beginning with a Phase 1 clinical study investigating a vaccine for COVID-19. Dosing of the initial cohort of the Phase 1 study is underway in Australia.
"Current adenovirus vaccines under investigation for COVID-19 and other infectious diseases are highly restricted in the amount of vaccine antigen they can deliver to cells," said Dr. Russell Rother, President and Chief Operating Officer of Tetherex. "The single-cycle adenovirus platform allows one round of robust vaccine antigen expression to occur without the generation of infectious virus particles which, in preclinical models, translates to a marked improvement in the ensuing immune response."
About the Single Cycle Adenovirus Vaccine Platform
The single-cycle adenovirus platform was developed to enhance the expression of target antigens, amplifying immune responses to infectious disease targets. Preclinical studies have demonstrated that the single-cycle adenovirus can increase target antigen expression up to 100-fold over currently utilized replication defective adenovirus vaccines. Intranasal administration of single-cycle vaccine elicits both systemic and mucosal immune responses. A mucosal response allows the immune system to encounter respiratory viruses like SARS-CoV-2 at the site of entry while the viral titers are lower. The platform also provides a robust manufacturing and supply chain paradigm relative to other vaccine platforms, such as mRNA.
Tetherex's Phase 1 open label study, designed to assess safety, reactogenicity and immunogenicity of the single-cycle adenovirus vaccine, is expected to recruit a total of approximately 80 healthy volunteers and includes both a single ascending dose group and a multiple dose group. Subjects will receive the vaccine via either intramuscular or intranasal administration.
The study site is Nucleus Network in Brisbane, and Dr Paul Griffin Nucleus Network's Principal Investigator said:
"The covid 19 global pandemic continues to impact lives around the world. We are very fortunate to have developed a number of vaccines for Covid-19 already that are safe and highly effective. These vaccines are beginning to give us the capacity to start to reduce the impact of this viral infection, however it's clear there are certain properties of these vaccines that we would ideally like to improve upon such as having a vaccine that could be given via a route other than needle and syringe and perhaps a vaccine that could further reduce the ability for a vaccinated individual to become infected in the first place, a so called transmission blocking vaccine. A vaccine given intranasally has the potential to achieve some of these objects hence I am very excited to be the principal Investigator on the Tetherex clinical trial."
"The addition of this novel vaccine platform to the Tetherex portfolio significantly expands our ability to leverage our scientific and clinical development expertise and broadens our overall technology base. This reduces risk to our investors while providing the potential of significant upside," said Dr. Scott Rollins, Chairman and Chief Executive Officer of Tetherex. "The platform will be utilized to target multiple infectious diseases which allows Tetherex to seek partnerships and alliances for the ever-expanding infectious disease marketplace."
About Avance Clinical
Avance Clinical is the largest full-service Australian CRO focussed on delivering quality clinical trials in Australia and New Zealand for international biotechs. Avance Clinical has been delivering CRO services in the region for the past 24 years. Avance is accredited by the office of the gene technology regulator (OGTR) and has experience with the level of complexity involved in the granting of licenses from OGTR. This accreditation allows Avance to take responsibility, on behalf of clients, for the execution of trials which involve genetically modified organism products.
The company's clients are international biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. Avance Clinical delivers customised solutions designed around specific client needs rather than a one size fits all approach. As a company Avance Clinical has focused on state-of-the-art technology and systems across all functional areas to provide clients with the most effective processes.
Medidata, Oracle, and Medrio are just some of our technology partners. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of candidates who demonstrate passion and expertise in their chosen field. Visit http://www.avancecro.com for more information.
Excellence in Business Award 2021
Frost & Sullivan Asia-Pacific CRO Market Leadership Award 2020
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
DOCOMO to Conduct Open RAN Field Trials with Ooredoo, Smart and StarHub
Feb 27, 2024 19:53 JST
CleverTap partners with Zoomcar to drive customer engagement on their app
Feb 27, 2024 18:00 JST
NEC Selected by NTT DOCOMO as a Virtualized Radio Access Network (vRAN) Vendor
Feb 26, 2024 17:54 JST
Fujitsu and Celonis Expand Strategic Global Partnership
Feb 26, 2024 15:40 JST
Mitsubishi Corporation's Sale of Exportadora de Sal, S.A. de C.V., a Salt Production Company in Mexico
Feb 26, 2024 14:29 JST
'MMVO,' Mazda's Production Base in Mexico Marks its 10th Anniversary
Feb 26, 2024 14:00 JST
Mitsubishi Electric Building Solutions to Supply Elevators and Escalators for New Capital Relocation Project in Indonesia
Feb 26, 2024 11:00 JST
Clear Mobitel Successfully Deploys NEC 5G SA Cloud Native Core Network to Accelerate the Adoption of Innovative 5G Solutions in the UK and the Channel Islands
Feb 22, 2024 17:13 JST
NEC UPF Achieves Industry-Leading High Performance in 5G Core Networks, reaching 1.3Tbps Throughput
Feb 22, 2024 16:10 JST
DOCOMO and NTT Expand 6G Collaborations with SK Telecom and Rohde & Schwarz
Feb 22, 2024 15:33 JST
Successful demonstration of computing and mobile networks convergence to provide diverse services in the 6G era
Feb 22, 2024 13:18 JST
Fujitsu introduces "Uvance Wayfinders", expanded and strengthened consulting capabilities to deliver cross-industry business value
Feb 22, 2024 12:05 JST
Fujitsu delivers new supercomputer system to Japan Meteorological Agency to improve prediction accuracy for typhoons and torrential rain
Feb 21, 2024 16:38 JST
MHI Group Presents "Best Innovation 2023" Awards for Activities that Contribute to Protecting the Environment
Feb 21, 2024 16:28 JST
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
Feb 21, 2024 15:26 JST
NEC, Arm, Qualcomm, Red Hat, and Hewlett Packard Enterprise demonstrate Open vRAN and 5G Core UPF using Arm-based CPUs
Feb 21, 2024 14:09 JST
NEC launches new User Plane Function (UPF) product for telecom operators, aiming to achieve networks for the Beyond 5G/6G era
Feb 21, 2024 11:33 JST
TANAKA to Provide Pure Gold, Pure Silver, and Pure Bronze Medals for the Tokyo Marathon 2024
Feb 21, 2024 04:00 JST
Fujitsu collaborates with QuTech in development of new technology for freezing electronics to control diamond spin qubits
Feb 20, 2024 21:28 JST
NTT DOCOMO and SK Telecom Release White Paper on Base Station Equipment Utilizing Virtualization Technology
Feb 20, 2024 15:32 JST